QUATRx Pharmaceuticals

QUATRx is building a portfolio of novel drug opportunities in a variety of therapeutic areas through in-licensing. Through the application of novel strategies, we plan to develop these rapidly, usually through to the end of Phase 2. This will add substantial value to the compounds prior to out-licensing to the final marketing partners, enabling QUATRx and its investors to realize highly attractive rates of return on the development investment and providing physicians access to innovative new therapies to treat diseases inadequately addressed by existing therapies. The initial focus of the company is drugs selectively targeting nuclear receptors. Nuclear receptors are proteins in the cell nucleus that act as receivers for a number of key hormones and govern a wide range of essential metabolic and developmental processes in the body. Through the understanding of nuclear receptors in drug design, new tissue selective drugs with enhanced benefits and fewer side effects can be developed, providing exciting opportunities for QUATRx.

Other therapeutic areas, including endocrine and metabolic diseases, cardiovascular disease and dermatology are also of particular interest to the Company, where clinical end points are well defined and development to the end of Phase 2 can be accomplished in a relatively short timescale.

Contact Details: 5430 Data Court, Suite 300 Ann Arbor MI 48108 United States of America Tel: 734 - 913-9900 Fax: 734 - 913-0743 Email: cnicholas@quatrx.com WWW: www.quatrx.com/

Loading...

BioNews Results for QUATRx Pharmaceuticals:
NanoBio ready for Big Pharma	Crains Detroit Business:  Aug 25 2008 8:13AM Matching: quatrx pharmaceuticals
InterWest Partners Announces Closing of $650 Million Venture Fund	TickerTech.com:  Aug 12 2008 11:45PM Matching: quatrx pharmaceuticals
InterWest Partners Announces Closing of $650 Million Venture Fund	Atlanta Business Chronicle:  Aug 11 2008 12:40PM Matching: quatrx pharmaceuticals
InterWest Partners Announces Closing of $650 Million Venture Fund	Business Journal of Milwaukee:  Aug 11 2008 12:30PM Matching: quatrx pharmaceuticals
InterWest Partners Announces Closing of $650 Million Venture Fund	San Francisco Business Times:  Aug 11 2008 12:26PM Matching: quatrx pharmaceuticals
Promote your company here: BioNewsCast - Press Release Distribution	→View more QUATRx Pharmaceuticals news.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 200 times since April 2007, the link to the organisation's website has been followed 38 times

Recent Search Terms used to find this page: quatrx com | @quatrx.com | QuatRx.com e-mail address | @quatrx.com email | QuatRx | @quatRx.com | at quatrx com | *quatrx.com | cNicholas @quatrx.com | quatrx.com | .

Search for more companies in Ann Arbor

Search for more companies in MI

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for QUATRx Pharmaceuticals